Liver Biotransformation
Liver Biotransformation - Related Videos
01:16
Drug Biotransformation: Overview
0 Views •
2023
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:28
Drug Biotransformation: Overview
0 Views •
2025
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
01:19
Factors Affecting Drug Biotransformation: Biological
0 Views •
2025
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity. Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects. Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
12:35
In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion
0 Views •
Cited by 14 •
2011
The study of liver sinusoidal endothelial cells (SECs) must be performed with primary cells obtained from the animal as no cell lines exist. This method relies on liver digestion and differential centrifugation for SEC purification for subsequent culturing and experimentation.
01:21
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
0 Views •
2025
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism. The drug's acidity or basicity is essential in determining the metabolic...
FAQs
The sequence and balance of hepatic reactions help determine what happens to a drug after absorption. Phase I cytochrome P450 oxidation can introduce or expose functional groups, creating metabolites that may then undergo Phase II conjugation. Because these stages alter chemical properties, they can change a compound’s potency, duration of action, and suitability for elimination.
Phase I and Phase II do not serve identical roles. Phase I modifies a compound through reactions such as oxidation, whereas Phase II attaches a molecule such as glucuronic acid. This distinction matters because the resulting metabolites and their handling can differ, allowing pharmacologists to connect a drug’s chemical transformation with its later transport and excretion.
The first-pass component of liver biotransformation can alter the amount of active compound available after absorption. As a result, hepatic processing may influence the observed potency and duration of a drug’s effects. Considering this factor is important when interpreting pharmacological responses and selecting a dose that reflects how the compound is handled in the body.
Metabolism is only part of the removal pathway. After enzymatic conversion, transport processes and biliary or urinary excretion help move products out of the body. This connection explains why studying biotransformation requires attention not only to reaction chemistry, but also to how metabolites are handled afterward and which elimination route contributes to their removal.
Cytochrome P450 activity is pharmacologically important because changes in enzymatic processing can alter metabolite formation and drug action. When compounds affect one another’s biotransformation, interactions may change potency, duration, or toxicity. Evaluating these pathways therefore helps researchers anticipate safety concerns rather than treating metabolism as a purely chemical transformation.
Patient variability is a central reason to study liver biotransformation. Differences in how individuals process drugs can contribute to variation in potency, duration, and toxicity. Pharmacological assessment of these pathways supports dose selection by linking metabolic behavior with expected therapeutic and safety outcomes, helping investigators account for responses that may not be uniform across patients.
During drug development, biotransformation findings contribute to decisions about whether a candidate has an acceptable safety profile. Researchers can examine Phase I and Phase II processing together with transport and excretion to understand how metabolites are handled and how they may influence drug action. This broader view supports the development of safer therapeutics and more informed pharmacological evaluation.